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Abstract
Background and Objectives: This paper aims to describe 
and compare the characteristics of 2 stroke populations in 
Singapore and in St. Louis, USA, and to document throm-
bolysis rates and contrast factors associated with its uptake 
in both populations. Methods: The stroke populations de-
scribed were from the Singapore Stroke Registry (SSR) in 
 Singapore and the Cognitive Rehabilitation Research Group 
Stroke Registry (CRRGSR) in St. Louis, MO, USA. The registries 
were compared in terms of demographics and stroke risk 
factor history. Logistic regression was used to determine fac-
tors associated with thrombolysis uptake. Results: A total of 
39,323 and 8,106 episodes were recorded in SSR and CRRG-
SR, respectively, from 2005 to 2012. Compared to CRRGSR, 
patients in SSR were older, male, and from the ethnic major-
ity. Thrombolysis rates in SSR and CRRGSR were 2.5 and 8.2%, 
respectively, for the study period. History of ischemic heart 
disease or atrial fibrillation was associated with increased 
uptake in both populations, while history of stroke was as-
sociated with lower uptake. For SSR, younger age and males 
were associated with increased uptake, while having a his-
tory of smoking or diabetes was associated with decreased 
uptake. For CRRGSR, ethnic minority status was associated 
with decreased uptake. Conclusions: The comparison of 
stroke populations in Singapore and St Louis revealed dis-
tinct differences in clinicodemographics of the 2 groups. 
Thrombolysis uptake was driven by nonethnicity demo-
graphics in Singapore. Ethnicity was the only demographic 
driver of uptake in the CRRGSR population, highlighting the 
need to target ethnic minorities in increasing access to 
thrombolysis. © 2019 S. Karger AG, Basel
Introduction
Thrombolysis via intravenous recombinant tissue 
plasminogen activator (rtPA) is a recommended treat-
ment for ischemic strokes with optimal recovery rates 
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documented when administered within 3 h from stroke 
onset and moderate recovery for 3–4.5 h from onset [1]. 
Administration is traditionally carried out within stroke 
centers or hospitals with expertise and access to facilities 
such as cerebral angiography [2]. Thrombolysis rates re-
ported in stroke registries vary widely across regions, 
from 0.6% in Taiwan [3] to 28% in Germany [4], due to 
different treatment type and time intervals from onset 
considered. Delivery of treatment has primarily been as-
sociated with health system factors, such as time to stroke 
discovery and expertise [5], but patient-level factors such 
as demographic characteristics and risk factors have also 
been influential on delivery of thrombolysis [6]. Hence, 
there is a need to understand thrombolysis use and its 
patient-level drivers, as well as its variation across differ-
ent countries.
The global burden of stroke on populations worldwide 
is well established, causing the second highest disability 
adjusted life years in the world [7]. However, few studies 
focus on contrasting differences in stroke burden be-
tween Asian and Western stroke populations [8, 9]. A de-
tailed comparison of individual-level stroke data from 
USA and Singapore will allow an examination of demo-
graphic and clinical characteristics of each population 
and facilitate better understanding of the clinical drivers 
and health challenges between the Asian and Western 
contexts. Therefore, the first aim of this paper was to de-
scribe and compare the stroke populations from hospitals 
in Singapore and USA, in terms of demographics, risk 
factor history, and thrombolysis rates. The second aim 
was to contrast the factors associated with use of throm-
bolytic therapy between the 2 registries. This study is the 
first to explore stroke in 2 multiethnic countries across 
Asian and Western contexts. 
Methods
Two stroke registry datasets from Singapore and USA were 
combined and analyzed. Ethics approval for the analysis was ob-
tained from the Institutional Review Board of the National Uni-
versity of Singapore and Washington University in St Louis. The 
methodology of data collection for both datasets has been de-
scribed in detail elsewhere [10–12]. In brief, the dataset from 
 Singapore consisted of deidentified stroke episodes from the 
 Singapore Stroke Registry (SSR), accessed via the National Regis-
try of Diseases Office (NRDO) under the Ministry of Health 
(MOH). The SSR received stroke case notifications from (1) all 
public healthcare institutions via the Hospital In-patient Dis-
charge Summary, (2) MOH via information on medical claims to 
the government (MediClaims list), and (3) the national death reg-
istry. NRDO’s Registry Coordinators verified the cases and ex-
tracted the detailed clinical information required by SSR, covering 
about 94% of strokes occurring in the country. 
The stroke registry dataset from the USA consisted of stroke 
episodes from a prospective cohort of stroke patients served by the 
Comprehensive Stroke Center at the Barnes-Jewish Hospital 
(BJH) in St Louis, Missouri, collected by the Cognitive Rehabilita-
tion Research Group (CRRG) at Washington University in St 
 Louis. Consent for follow-up was given at point of interview dur-
ing the hospital stay. Data were extracted from the hospital system 
for patients admitted between 1999 and 2017. Case notes were ver-
ified by registry coordinators and all patient information were ex-
ported into a standard report form. The deidentified CRRG data 
were combined with the SSR data in NRDO. Variables common to 
both registries were identified and reviewed to ensure the same 
definitions and categorizations were used. Thrombolysis was de-
fined as the use of intravenous tPA in both registries.
Statistical Analysis
Only ischemic strokes that occurred between January 1, 2005, 
and December 31, 2012 (the overlapping period) in both registries 
were included in this study, using the definition of stroke by the 
World Health Organization with supporting radiological data and 
a set of International Classification of Diseases codes for ischemic 
stroke [10]. The 2 stroke populations were compared in terms of 
demographic factors and history of risk factors. The thrombolysis 
rates for the study period and by year were also assessed. Ethnici-
ties in both populations were regrouped into majority and minor-
ity groups. For the SSR, patients of Chinese ethnicity were identi-
fied as the majority, while Malay, Indian, and other ethnicities 
were grouped together as the ethnic minority. For the CRRG 
Stroke Registry (CRRGSR), Caucasians were identified as the ma-
jority while African-American, Hispanic, Asian, and other ethnic-
ities were grouped as the ethnic minority. 
To examine the factors associated with thrombolysis, logistic 
regression was used with uptake as the outcome and models were 
built using pooled data from both countries, as well as for each 
country separately. Unadjusted logistic regression was used to 
identify factors independently associated with uptake, using a p 
value criterion of 0.05 and below for statistical significance. For 
multivariable analysis, all factors were included in the same model, 
and a backward stepwise approach was implemented for variable 
selection, using the abovementioned p value criterion to obtain a 
parsimonious model. ORs and their corresponding 95% CI were 
reported for each factor. Sensitivity analyses were carried out by 
building the same regression models using the respective ethnic 
groups of the 2 populations. All analyses were performed in RStu-
dio [13].
Results
Clinicodemographic Profile of Both Stroke Populations
A total of 47,429 ischemic strokes were recorded from 
2005 to 2012, with 39,323 and 8,106 episodes recorded in 
the SSR and CRRGSR, respectively (Table 1). The 2 stroke 
populations differed in most demographic characteris-
tics, with a larger proportion of patients in the SSR being 
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above 65 years old and belonging to the male sex or ethnic 
majority. The distributions of risk factors for stroke dif-
fered significantly between the 2 populations, with pa-
tients in the CRRGSR exhibiting a higher prevalence 
across all investigated factors, except for diabetes mellitus 
(SSR 40.4%; CRRGSR 23.5%). For thrombolysis rates, 
2.5% of episodes in the SSR were treated with thromboly-
sis, a lower rate in comparison to 8.2% in the CRRGSR 
(Table 1). Examining the rates by year, uptake increased 
over the study period in both countries (Fig. 1). 
Table 1. Characteristics of study populations from SSR (Singapore) and CRRGSR (St Louis, MO, USA)
Combined (n = 47,429) SSR (n = 39,323) CRRGSR (n = 8,106)
n (%) n (%) n (%)
Year of admission
2005 5,332 (11.2) 4,662 (11.9) 670 (8.3)
2006 5,317 (11.2) 4,600 (11.7) 717 (8.8)
2007 5,641 (11.9) 4,801 (12.2) 840 (10.4)
2008 5,678 (12.0) 4,689 (11.9) 989 (12.2)
2009 5,979 (12.6) 4,887 (12.4) 1,092 (13.5)
2010 6,248 (13.2) 5,025 (12.8) 1,223 (15.1)
2011 6,591 (13.9) 5,219 (13.3) 1,372 (16.9)
2012 6,643 (14.0) 5,440 (13.8) 1,203 (14.8)
Age at stroke onset, years
Median (IQR) 68.0 (58.0–78.0) 69.0 (59.0–78.0) 64.0 (53.0–76.0)
Range 15.0–115.0 15.0–115.0 18.0–90.0
Age group
<50 years 4,829 (10.2) 3,382 (8.6%) 1,447 (17.9)
50–64 years 14,606 (30.8) 11,920 (30.3) 2,686 (33.1)
≥65 years 27,994 (59.0) 24,021 (61.1) 3,973 (49.0)
Gender
Female 21,436 (45.2) 17,228 (43.8) 4,208 (51.9)
Male 25,993 (54.8) 22,095 (56.2) 3,898 (48.1)
Ethnic group
Majority 34,043 (71.8) 29,519 (75.1) 4,524 (55.8)
Minority 13,386 (28.2) 9,804 (24.9) 3,582 (44.2)
Risk factors for stroke
TIA 2,797 (5.9) 1,766 (4.5) 1,031 (12.7)
Stroke 12,665 (26.7) 10,237 (26.0) 2,428 (30.0)
Hypertension 36,206 (76.3) 29,868 (76.0) 6,338 (78.2)
Diabetes mellitus 17,781 (37.5) 15,876 (40.4) 1,905 (23.5)
Ischemic heart disease 12,092 (25.5) 9,612 (24.4) 2,480 (30.6)
Atrial fibrillation 5,808 (12.2) 4,636 (11.8) 1,172 (14.5)
Valvular heart disease 1,302 (2.7) 898 (2.3) 404 (5.0)
Peripheral heart disease 1,996 (4.2) 1,408 (3.6) 588 (7.3)
Smoking 18,421 (38.8) 15,169 (38.6) 3,252 (40.1)
Inpatient events
CT/head scan 46,292 (97.6) 39,237 (99.8) 7,055 (87.0)
Thrombolysis 1,647 (3.5) 985 (2.5) 662 (8.2)
Length of stay, days
Median (IQR) 5.0 (3.0–10.0) 6.0 (3.0–11.0) 3.0 (2.0–7.0)
Maximum 400.0 388.0 400.0
Discharge destination
Deceased 3,317 (7.0) 2,957 (7.5) 360 (4.4)
Home (no rehabilitation) 17,812 (37.6) 15,915 (40.5) 1,897 (23.4)
Home (with rehabilitation) 8,039 (16.9) 5,915 (15.0) 2,124 (26.2)
Nursing home 2,534 (5.3) 1,655 (4.2) 879 (10.8)
Other hospitals 3,071 (6.5) 2,891 (7.4) 180 (2.2)
Inpatient rehabilitation hospital 12,656 (26.7) 9,990 (25.4) 2,666 (32.9)
TIA, transient ischemic attack; SSR, Singapore Stroke Registry; CRRGSR, Cognitive Rehabilitation Research 
Group Stroke Registry; IQR, interquartile range.
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Factors Associated with Thrombolysis Uptake
From bivariable analysis of pooled information from 
both stroke populations (Table 2), being of older age was 
associated with lower thrombolysis uptake (OR 0.99, 95% 
CI 0.99–0.99), while male sex (1.17, 1.06–1.29) and ethnic 
minority (1.16, 1.04–1.29) were associated with higher 
thrombolysis uptake. Clinical risk factors such as having 
a history of transient ischemic attack (TIA; 1.28, 1.06–
1.54), ischemic heart disease (1.30, 1.17–1.45), or atrial 
fibrillation (1.71, 1.51–1.94) were also associated with 
higher uptake. In contrast, history of stroke (0.58, 0.51–
0.66) or diabetes (0.67, 0.60–0.74) was associated with 
lower rates of thrombolysis. In addition, uptake was sig-
nificantly higher in all years after 2005, with the highest 
in 2012 (5.99, 4.53–7.93). In the multivariable analysis, 
younger age (0.99, 0.99–1.00), males (1.20, 1.08–1.33), 
history of ischemic heart disease (1.29, 1.15–1.46), and 
atrial fibrillation (1.74, 1.51–1.99) remained associated 
with thrombolysis use upon admission, while history of 
stroke (0.53, 0.47–0.61) or diabetes (0.81, 0.72–0.90) was 
associated with lower uptake.
Examining only the SSR population (Table 3), similar 
bivariable associations with thrombolysis uptake were 
observed, except for ethnicity (1.12, 0.97–1.29) and his-
tory of TIA (1.24, 0.94–1.64), which were no longer sta-
tistically significant. In the multivariable analysis, smok-
ing was additionally found to be associated with lower 
uptake (0.78, 0.67–0.90). Sensitivity analyses did not 
show any statistically significant association of the differ-
ent ethnic minorities with thrombolysis uptake (online 
suppl. Table S1; for all online suppl. material, see www.
karger.com/doi/10.1159/000502278). The uptake in-
creased significantly from 2007 onwards (2007: 2.78, 
1.73–4.47; 2012: 9.35, 6.09–14.36).
For the CRRGSR population, bivariable associations 
were found similar to that in the pooled analysis, except 
for sex (1.13, 0.96–1.33) and history of diabetes (1.03, 
0.86–1.24), which were no longer statistically significant 
(Table 3). In multivariable analysis, history of ischemic 
heart disease (1.22, 1.03–1.45) and atrial fibrillation (1.45, 
1.18–1.79) were found to be associated with greater up-
take of thrombolysis, while ethnic minority status (0.83, 
0.70–0.98) and history of stroke (0.66, 0.54–0.80) were as-
sociated with lower uptake. Uptake increased significant-
ly only from 2009 onwards (2009: 1.65, 1.09–2.48; 2012: 
2.59, 1.76–3.81). Sensitivity analyses revealed the African-
American minority, constituting 42.7% of the population, 
to be driving the association of the ethnic minority with 
lower thrombolysis uptake (online suppl. Table S1). 
Discussion/Conclusion
The comparison of stroke populations from hospitals 
in Singapore and St Louis revealed distinct differences in 
clinicodemographics of the 2 groups. Findings revealed 
differing age distributions between the 2 registries, with 
younger patients in the CRRGSR than in the SSR. Hyper-
tension, smoking, ischemic heart disease, diabetes, and 
prior stroke remain the top risk factors for both popula-
tions. This similarity in risk factor profile across these 
Western and Asian populations is consistent with the 
findings from comparative studies [8, 9], including the 



































Fig. 1. Thrombolysis rates over time in 
CRRGSR and SSR. SSR, Singapore Stroke 
Registry; CRRGSR, Cognitive Rehabilita-
tion Research Group Stroke Registry.
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within the top 10 attributable risk factors for stroke in the 
high-income Asia-Pacific region [14], the implications of 
an increasing diabetes prevalence would include an in-
crease in stroke burden in later years, motivating the need 
to ensure that the burden of diabetes in Singapore is ad-
dressed to tackle the future stroke burden in the country.
The increase in thrombolysis rates over time suggests 
increased awareness and advocacy of thrombolysis as an 
established stroke treatment [15]. The higher thrombolysis 
rates in the CRRGSR demonstrate the importance of sys-
tem-level programs to increase quality of care and can be 
attributed to a decade long nationwide effort to improve 
hospital processes [16]. The Get With The Guidelines cam-
paign by the American Stroke Association in the USA re-
quires enrolled hospitals to achieve certain standards of 
care, such as meeting targeted rates of brain scans and 
thrombolysis of patients. The association also recognizes 
hospitals that achieve excellence in these areas, encourag-
ing greater adherence to clinical guidelines and subse-
quently increasing thrombolysis rates. In Singapore, the 
publication of the first set of Clinical Practice Guidelines 
(CPG) for stroke and TIAs in 2008 by the MOH could have 
contributed to the steady increase in thrombolysis rates in 
ensuing years. The CPG recommended the use of tPA for 
thrombolysis within 3 h of stroke onset [17]. This recom-
mendation was revised in 2013 (after the period of study), 
in accordance with newer clinical evidence which demon-
strated benefit to patients treated with tPA during the 
3–4.5 h window period [18]. In addition to the use of the 
CPG, implementation of a guideline similar to Get With 
The Guidelines in Singapore could potentially encourage 
a further system-level increase in thrombolysis rates.
Table 2. Logistic regression analyses of thrombolysis rates, using pooled data
Bivariable OR (95% CI) Multivariable OR (95% CI)
Country
SG 1.00 1.00
USA 3.46 (3.13–3.83)*** 3.10 (2.79–3.45)***
Demographics
Age at admission 0.99 (0.99–0.99)*** 0.99 (0.99–1.00)***
Gender





2006 1.40 (0.99–1.97) 1.36 (0.97–1.92)
2007 1.91 (1.39–2.63) 1.80 (1.30–2.48)
2008 2.48 (1.82–3.37) 2.26 (1.66–3.08)
2009 3.40 (2.53–4.57) 3.06 (2.28–4.12)
2010 3.91 (2.92–5.22) 3.42 (2.56–4.58)
2011 5.66 (4.28–7.50) 4.87 (3.67–6.46)
2012 5.99 (4.53–7.93) 5.40 (4.07–7.15)
Risk factors
TIA 1.28 (1.06–1.54)*
Previous stroke 0.58 (0.51–0.66)*** 0.53 (0.47–0.61)***
Hypertension 0.94 (0.84–1.05)
Diabetes mellitus 0.67 (0.60–0.74)*** 0.81 (0.72–0.90)***
Ischemic heart disease 1.30 (1.17–1.45)*** 1.29 (1.15–1.46)***
Atrial fibrillation 1.71 (1.51–1.94)*** 1.74 (1.51–1.99)***
Valvular heart disease 1.26 (0.96–1.65)





TIA, transient ischemic attack.
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The results of the multivariable analysis suggest differ-
ing barriers to stroke thrombolysis in both countries. Up-
take of treatment appears to be dependent on age, sex, and 
risk factors of stroke patients in Singapore. We found fe-
males and smokers were associated with lower thrombol-
ysis uptake in the SSR, which are in agreement with previ-
ous studies [19, 20]. The lower thrombolysis rates ob-
served in females could potentially be attributed to delay 
in arrival time or higher stroke severity, which would pre-
clude them from treatment [20, 21]. The lower treatment 
rates in smokers may be attributed to higher stroke sever-
ity and subsequently treatment ineligibility for smokers 
with small-vessel occlusions [22]. However, we were un-
able to perform a subgroup analysis to confirm this as isch-
emic stroke subtype information was not collected in this 
study. In the United States, ethnicity in contrast appears 
to be a dominant factor in the delivery of stroke treatment 
to a patient. The evident ethnic disparity in thrombolysis 
rates in the CRRGSR is supported by the wealth of litera-
ture indicating racial-ethnic disparities in stroke care be-
tween white and minority communities [23–26]. Our re-
sults support the discussion advocating greater measures 
to narrow the gap in care for the minorities in the country 
and to address the underlying drivers of this disparity [23]. 
This study has several strengths. This study examined 
2 multiethnic stroke populations using individual-level 
data, revealing associations of various factors with throm-
bolysis uptake. The completeness of coverage by the re-
spective registries, as well as the use of retrospective data 
from hospital records of all stroke admissions, minimized 
selection, and recall bias. Any bias was also likely to be 
nondifferential across the patients who received and did 
not receive thrombolysis. This was because the registries 
were set up with collecting routine stroke data as a pri-
mary purpose, and information collected would not be 
associated with the outcome of thrombolysis or any spe-
Table 3. Logistic regression analyses of thrombolysis rates, using country-specific data
SSR (n = 39,323) CRRGSR (n = 8,106)
bivariable OR (95% CI) multivariable OR (95% CI) bivariable OR (95% CI) multivariable OR (95% CI)
Demographics
Age at admission 0.98 (0.98–0.99)*** 0.98 (0.98–0.99)*** 1.01 (1.00–1.01)**
Gender
Male 1.37 (1.20–1.56)*** 1.38 (1.18–1.60)*** 1.13 (0.96–1.33)
Ethnicity
Minority 1.12 (0.97–1.29) 0.73 (0.62–0.86)*** 0.83 (0.70–0.98)*
Admission year
2005 1.00*** 1.00*** 1.00*** 1.00***
2006 1.06 (0.60–1.88) 1.04 (0.58–1.84) 1.55 (1.00–2.42) 1.55 (1.00–2.42)
2007 2.90 (1.80–4.66) 2.78 (1.73–4.47) 1.08 (0.69–1.71) 1.07 (0.68–1.69)
2008 4.76 (3.03–7.47) 4.56 (2.90–7.17) 0.79 (0.49–1.26) 0.80 (0.50–1.28)
2009 5.29 (3.39–8.27) 4.98 (3.19–7.79) 1.62 (1.08–2.44) 1.65 (1.09–2.48)
2010 5.99 (3.85–9.32) 5.62 (3.61–8.75) 1.81 (1.22–2.70) 1.82 (1.22–2.71)
2011 9.47 (6.16–14.56) 8.85 (5.75–13.61) 2.23 (1.52–3.27) 2.23 (1.51–3.28)
2012 10.04 (6.54–15.41) 9.35 (6.09–14.36) 2.58 (1.76–3.80) 2.59 (1.76–3.81)
Risk factors
TIA 1.24 (0.94–1.64) 0.76 (0.58–0.98)*
Previous stroke 0.46 (0.39–0.55)*** 0.48 (0.40–0.58)*** 0.66 (0.55–0.80)*** 0.66 (0.54–0.80)***
Hypertension 0.89 (0.77–1.03) 0.94 (0.78–1.14)
Diabetes mellitus 0.69 (0.60–0.79)*** 0.72 (0.63–0.83)*** 1.03 (0.86–1.24)
Ischemic heart disease 1.20 (1.04–1.38)* 1.41 (1.21–1.65)*** 1.23 (1.04–1.45)* 1.22 (1.03–1.45)*
Atrial fibrillation 1.70 (1.44–2.00)*** 1.89 (1.58–2.26)*** 1.53 (1.25–1.88)*** 1.45 (1.18–1.79)***
Valvular heart disease 1.16 (0.78–1.73) 0.90 (0.61–1.31)
Peripheral heart disease 0.93 (0.66–1.32) 0.98 (0.72–1.33)




SSR, Singapore Stroke Registry; CRRGSR, Cognitive Rehabilitation Research Group Stroke Registry; TIA, transient ischemic attack.
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cific characteristics of the patients. Attrition bias was 
minimal as all data were collected for a single admission, 
without the need for follow-up. As a nationwide stroke 
registry, the SSR would have reached all hospitalizations 
related to stroke in public hospitals, covering around 94% 
of all stroke cases in Singapore. Information collected is 
routine and standardized from the different hospitals, en-
suring quality of the data. The CRRGSR was also compre-
hensive in coverage as it covered all patients in the region 
of St. Louis, Missouri, who sought care for stroke at BJH, 
which is the largest hospital in the state.
Limitations of this study include the inability to capture 
the data of stroke patients who sought help at the private 
hospitals in Singapore or other hospitals in St Louis. The re-
sults obtained may not also be generalizable to other stroke 
populations in the rest of the United States due to variations 
in demographic makeup. Consequently, the findings of this 
study cannot be generalized to reflect any nation-level dif-
ferences in characteristics or trends. Furthermore, BJH as a 
regional stroke center receives stroke patients from neigh-
boring sites who may have already received thrombolysis 
before transferring to BJH. The treatment rates reported in 
this paper would then reflect the thrombolysis usage in the 
hospital itself and would be a underestimate of the rate in the 
state. In addition, the uptake of thrombolysis was modeled 
in this paper to be dependent on patient-centric factors and 
did not account for the impact of health system factors af-
fecting the administration of thrombolysis [5, 6]. In particu-
lar, history of medication use and door- or onset-to-needle 
time were not included as they were not available for the 
study period in both datasets. Also, stroke severity, mea-
sured by indices such as the National Institutes of Health 
(NIH) Stroke Scale [27], was similarly not available in the 
SSR for the study period as it was not routinely collected in 
hospitals in Singapore, limiting any conclusions to be made 
for the association between the stroke severity and throm-
bolysis uptake. The findings could also be affected by differ-
ences in treatment indications between the 2 populations, 
such as indications for patients aged 80 and above within 
4.5 h of stroke onset by the American Stroke Association but 
not by the CPG. The lack of such information related to the 
eligibility of stroke patients arriving at the hospital could 
also potentially pose as confounders in identifying factors 
associated with thrombolysis uptake and should be obtained 
to refine the analysis in future work. 
The detailed comparison of stroke registry data from 
Singapore and St Louis suggests that the characteristics of 
stroke patients in the 2 populations generally differ. Rates 
of thrombolysis were lower in Singapore than in the CRRG-
SR. Factors influencing the administration of thrombolysis 
upon admission were similar in clinical risk factors across 
the 2 registries, but differed in demographic aspects, with 
age- and sex-driving uptake in Singapore, and ethnicity in 
the CRRG stroke population. However, both trends in up-
take appear to be on the rise, suggesting that the increasing 
awareness and advocacy of thrombolysis may be translat-
ing to greater use over the period of 2005–2012. 
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